Palmetto GBA issues final local coverage determination for ProMark

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

METAMARK GENETICS INC. said that Palmetto GBA issued final local coverage determination for ProMark, a proteomic prognostic test for early-stage prostate cancer. The finalized ProMark LCD is effective Oct. 10, 2016, and approves Medicare reimbursement coverage for eligible prostate cancer patients to help determine which patients can be conservatively managed rather than treated with definitive...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login